KGKevin A. Glenn

Kevin A. Glenn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin A. Glenn has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Hsiang Wen

    Department of Medicine, Carver College of Medicine, and

    5 shared publications
  • Hsiang M. Wen

    3 shared publications
  • Rick F. Nelson

    ‡Veterans Affairs Medical Center, Iowa City, Iowa 52242, the §Department of Internal Medicine and ¶Department of Otolaryngology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, ∥Kansas City University of Medicine and Biosciences, Kansas City, Kansas 64106, and the **Department of Neurology, University of Michigan Health System, Ann Arbor, Michigan 48109

    3 shared publications
  • Adam Mallinger

    Kansas City University of Medicine and Biosciences, Kansas City, MO 64106, USA

    2 shared publications
  • David J. Shapiro

    Departments of Biochemistry (X.J., N.M.P., D.J.S.), University of Illinois at Urbana-Champaign, Urbana, Illinois 61801

    2 shared publications
  • Geoffrey M. Dankle

    2 shared publications

Latest Publications

  • TorsinA and protein quality control

    by Kara Leigh Gordon, Pedro Gonzalez-Alegre, Christopher Benson, Andrew Russo, Stefan Strack, Kevin Glenn

    DYT1 dystonia (DYT1) is a disabling inherited neurological disorder with juvenile onset. The genetic mutation in DYT1 leads to the deletion of a glutamic acid (E) residue in the protein torsinA. The function of torsinA and how the mutation leads to DYT1 is poorly understood. We hypothesize that how efficiently the disease-linked mutant protein is cleared may be critical for DYT1 pathogenesis. Therefore we explored mechanisms of torsinA catabolism, employing biochemical, cellular, and animal-based approaches. We asked if torsinA(wt) and torsinA(DE) are degraded preferentially through different catabolic mechanisms, specifically the ubiquitin proteasome pathway (UPP) and autophagy. We determined that torsinA(wt) is cleared by autophagy while torsinA(DE) is efficiently degraded by the UPP suggesting degradation processes can modulate torsinA(DE) levels. Proteins implicated in recognizing motifs on torsinA(DE) for targeting to the UPP represent candidate proteins that may modify DYT1 pathogenesis. We examined how removal of the hydrophobic domain and mutation of glycosylated asparagine residues on torsinA altered stability and catabolic mechanism. We found the glycosylation sites on torsinA are important for stability modulate its degradation through the UPP. F-box G-domain protein 1 (FBG1) has been implicated in degradation of glycosylated ER proteins. We hypothesized that FBG1 would promote torsinA degradation and demonstrated that FBG1 modulates levels of torsinA in a non-canonical manner through the UPP and autophagy. We examined if lack of FBG1 in a torsinA(DE) mouse model altered motor phenotypes. We saw no effect which suggests FBG1 does not alter DYT1 pathogenesis despite its promotion of torsinA(DE) degradation. In addition, we explored a potential mechanism for the previously described role of torsinA in modulating cytoplasmic protein aggregation. We hypothesized this endoplasmic reticulum (ER) resident protein would indirectly alter cytoplasmic protein aggregation through modulation of ER stress. We employed a poly-glutamine expanded repeat protein and pharmacological ER stressors to determine that torsinA does not alter poly-glutamine protein aggregation nor ER stress in a mammalian system. In summary, this thesis suggests proteins involved in the catabolism of torsinA(DE) may modify DYT1 pathogenesis and that torsinA and its DYT1-linked mutant are model proteins for investigating ER protein degradation by the UPP and autophagy.

  • The Virtual Hospitalist: A Single‐Site Implementation Bringing Hospitalist Coverage to Critical Access Hospitals

    by Ethan F. Kuperman, Eric L. Linson, Kate Klefstad, Evelyn Perry, Kevin Glenn

    BACKGROUND: On‐site hospitalist care can improve patient care, but it is economically infeasible for small critical access hospitals (CAHs). A telemedicine “virtual hospitalist” may expand CAH capabilities at a fractional cost of an on‐site provider.OBJECTIVE: To evaluate the impact of a virtual hospitalist on transfers from a CAH to outside hospitals.DESIGN, SETTING, AND PARTICIPANTS: A six‐month pilot program providing “virtual hospitalist” coverage to patients at a CAH in rural Iowa.MEASUREMENTS: The primary outcome was the rate of outside transfers from the CAH Emergency Department (ED). The secondary outcomes included transfer from either the ED or the inpatient wards, daily census, length of stay, transfers after admission, virtual hospitalist time commitment, and patient and staff satisfaction. The preceding 24‐week baseline was compared with 24 weeks after implementation, excluding a two‐week transition period.RESULTS: At baseline, there were 947 ED visits and 176 combined inpatient and observation encounters, compared to 930 and 176 after implementation, respectively. Outside transfers from the ED decreased from 16.6% to 10.5% (157/947 to 98/930, P < .001), and transfers at any time decreased from 17.3% to 11.9% (164/947 to 111/930, P < .001). Daily census, length of stay, and transfers after admission were unchanged. Time commitment for a virtual hospitalist was 35 minutes per patient per day. The intervention was well received by the CAH staff and patients.CONCLUSIONS: The virtual hospitalist model increased the percentage of ED patients who could safely receive their care locally. A single virtual hospitalist may be able to cover multiple CAHs simultaneously.


  • Open Access

    Disruption of Protein Processing in the Endoplasmic Reticulum of DYT1Knock-inMice Implicates Novel Pathways in Dystonia Pathogenesis

    by Genevieve Beauvais, Nicole M. Bode, Jaime L. Watson, Hsiang Wen, Kevin A. Glenn, Hiroyuki Kawano, N. Charles Harata, Michelle E. Ehrlich, Pedro Gonzalez-Alegre

    Dystonia type 1 (DYT1) is a dominantly inherited neurological disease caused by mutations inTOR1A, the gene encoding the endoplasmic reticulum (ER)-resident protein torsinA. Previous work mostly completed in cell-based systems suggests that mutant torsinA alters protein processing in the secretory pathway. We hypothesized that inducing ER stress in the mammalian brainin vivowould trigger or exacerbate mutant torsinA-induced dysfunction. To test this hypothesis, we crossed DYT1knock-inwith p58(IPK)-null mice. The ER co-chaperone p58(IPK) interacts with BiP and assists in protein maturation by helping to fold ER cargo. Its deletion increases the cellular sensitivity to ER stress. We found a lower generation of DYT1knock-in/p58knock-outmice than expected from this cross, suggesting a developmental interaction that influences viability. However, surviving animals did not exhibit abnormal motor function. Analysis of brain tissue uncovered dysregulation of eiF2α and Akt/mTOR translational control pathways in the DYT1 brain, a finding confirmed in a second rodent model and in human brain. Finally, an unbiased proteomic analysis identified relevant changes in the neuronal protein landscape suggesting abnormal ER protein metabolism and calcium dysregulation. Functional studies confirmed the interaction between the DYT1 genotype and neuronal calcium dynamics. Overall, these findings advance our knowledge on dystonia, linking translational control pathways and calcium physiology to dystonia pathogenesis and identifying potential new pharmacological targets.SIGNIFICANCE STATEMENTDystonia type 1 (DYT1) is one of the different forms of inherited dystonia, a neurological disorder characterized by involuntary, disabling movements. DYT1 is caused by mutations in the gene that encodes the endoplasmic reticulum (ER)-resident protein torsinA. How mutant torsinA causes neuronal dysfunction remains unknown. Here, we show the behavioral and molecular consequences of stressing the ER in DYT1 mice by increasing the amount of misfolded proteins. This resulted in the generation of a reduced number of animals, evidence of abnormal ER protein processing and dysregulation of translational control pathways. The work described here proposes a shared mechanism for different forms of dystonia, links for the first time known biological pathways to dystonia pathogenesis, and uncovers potential pharmacological targets for its treatment.


  • Open Access

    FBG1 Is the Final Arbitrator of A1AT-Z Degradation

    by John H. Wen, Hsiang Wen, Katherine N. Gibson-Corley, Kevin A. Glenn

    Alpha-1 antitrypsin deficiency is the leading cause of childhood liver failure and one of the most common lethal genetic diseases. The disease-causing mutant A1AT-Z fails to fold correctly and accumulates in the endoplasmic reticulum (ER) of the liver, resulting in hepatic fibrosis and hepatocellular carcinoma in a subset of patients. Furthermore, A1AT-Z sequestration in hepatocytes leads to a reduction in A1AT secretion into the serum, causing panacinar emphysema in adults. The purpose of this work was to elucidate the details by which A1AT-Z is degraded in hepatic cell lines. We identified the ubiquitin ligase FBG1, which has been previously shown to degrade proteins by both the ubiquitin proteasome pathway and autophagy, as being key to A1AT-Z degradation. Using chemical and genetic approaches we show that FBG1 degrades A1AT-Z through both the ubiquitin proteasome system and autophagy. Overexpression of FBG1 decreases the half-life of A1AT-Z and knocking down FBG1 in a hepatic cell line, and in mice results in an increase in ATAT. Finally, we show that FBG1 degrades A1AT-Z through a Beclin1-dependent arm of autophagy. In our model, FBG1 acts as a safety ubiquitin ligase, whose function is to re-ubiquitinate ER proteins that have previously undergone de-ubiquitination to ensure they are degraded.


  • Open Access

    Tissue Standards Using Stain Free Gels as a Superior Approach for Aging Research

    by Hsiang M. Wen, Geoffrey M. Dankle, Kevin A. Glenn

    A good loading control is critical for accurate comparison of tissue protein levels in aged and young tissue. After reviewing the literature we discovered that the housekeeping proteins commonly used in Western analysis had significant drawbacks. The purpose of this study was to evaluate the linearity and reproducibility of common housekeeping proteins tubulin, actin and GAPDH compared to measures of total protein staining using Direct Blue and Stain Free gels. We found that measurements of total protein staining were superior to housekeeping proteins both in linearity and reproducibility in young and old mouse, liver, heart, and brain. Among the total protein staining methods, the Stain Free method was superior to Direct Blue, in terms of lower variability and higher accuracy in all tissues, at both ages.

  • Using a ubiquitin ligase as an unfolded protein sensor

    by Adam Mallinger, Hsiang M. Wen, Geoffrey M. Dankle, Kevin A. Glenn


  • Exploring the Influence of TorsinA Expression on Protein Quality Control

    by Kara L. Gordon, Kevin A. Glenn, Pedro Gonzalez-Alegre

    DYT1 dystonia is caused by a glutamic acid deletion (ΔE) in the endoplasmic reticulum (ER) protein torsinA. Previous studies suggest that torsinA modulates the aggregation of cytosolic misfolded proteins and ER stress responses, although the mechanisms underlying those effects remain unclear. In order to investigate the bases of these observations, we analyzed the interaction between torsinA expression, protein aggregation and ER stress in PC6.3 cells. Unexpectedly, we found that expression of torsinA(wt) or (ΔE) does not influence the inclusion formation by an expanded polyglutamine reporter protein in this cellular model. Furthermore, torsinA does not prevent the activation of ER stress induced by thapsigargin or the reducing agent DTT. Interestingly, DTT induces post-translational changes in torsinA, more prominently for torsinA(wt) than (ΔE). This work highlights the importance of model system selection for the study of torsinA function. Furthermore, it provides additional evidence suggesting that torsinA is sensitive to changes in the cellular redox potential.


  • Open Access

    FBG1 is a promiscuous ubiquitin ligase that sequesters APC2 and causes S-phase arrest.

    by Hsiang Wen, Namhun Kim, Ernesto J. Fuentes, Adam Mallinger, Pedro Gonzalez-Alegre, Kevin A. Glenn

    During cell proliferation, protein degradation is strictly regulated by the cell cycle and involves two complementary ubiquitin ligase complexes, the SCF (Skp, Cullin, F-box) and APC/C (Anaphase Promoting Complex/Cyclosome) ubiquitin ligases. SCF ligases are constitutively active and generally target only proteins after they have been selected for degradation, usually by phosphorylation. In contrast, APC/C complexes are themselves activated by phosphorylation and their substrates contain a targeting signal known as degron, a consensus amino acid sequence such as a D-Box. SCF complexes degrade proteins during the G1 phase. However, as DNA synthesis begins, the SCF complexes are degraded and APC/C complexes are activated. APC-2, a protein crucial to cell division, initiates anaphase by triggering the degradation of multiple proteins. This study explores an unexpected interaction between APC-2 and SCFFBG1. We found that FBG1 is a promiscuous ubiquitin ligase with many partners. Immunoprecipitation experiments demonstrate that FBG1 and APC2 interact directly. Mutagenesis-based experiments show that this interaction requires a D-Box found within the FBG1 F-box domain. Unexpectedly, we demonstrate that co-expression with FBG1 increases total APC2 levels. However, free APC2 is decreased, inhibiting cell proliferation. Finally, FACS analysis of cell populations expressing different forms of FBG1 demonstrate that this ubiquitin ligase induces S-phase arrest, illustrating the functional consequences of the interaction described. In summary, we have discovered a novel APC2 inhibitory activity of FBG1 independent from its function as ubiquitin ligase, providing the basis for future studies of FBG1 in aging and cancer.


  • Open Access

    Diversity in Tissue Expression, Substrate Binding, and SCF Complex Formation for a Lectin Family of Ubiquitin Ligases

    by Kevin A. Glenn, Rick F. Nelson, Hsiang M. Wen, Adam J. Mallinger, Henry L. Paulson